Trial · NCT00452673
Results by group100
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 100
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population | 50 mg Dasatinib + 825 mg/m^2Capecitabine | 1 | participants | ||
| Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population | 70 mg Dasatinib + 825 mg/m^2Capecitabine | 1 | participants | ||
| Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population | 70 mg Dasatinib + 1000 mg/m^2Capecitabine | 1 | participants | ||
| Number of Participants With Dose Limiting Toxicities Per Dose Level - Safety Population | 100 mg Dasatinib + 1000 mg/m^2Capecitabine | 2 | participants | ||
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 50 mg Dasatinib + 825 mg/m^2Capecitabine | Deaths within 30 days of last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 825 mg/m^2Capecitabine | Deaths within 30 days of last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 1000 mg/m^2Capecitabine | Deaths within 30 days of last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 100 mg Dasatinib + 1000 mg/m^2Capecitabine | Deaths within 30 days of last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 50 mg Dasatinib + 825 mg/m^2Capecitabine | Deaths reported beyond 30 days post last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 825 mg/m^2Capecitabine | Deaths reported beyond 30 days post last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 1000 mg/m^2Capecitabine | Deaths reported beyond 30 days post last dose | 0 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 100 mg Dasatinib + 1000 mg/m^2Capecitabine | Deaths reported beyond 30 days post last dose | 4 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 50 mg Dasatinib + 825 mg/m^2Capecitabine | Participants with SAEs | 2 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 825 mg/m^2Capecitabine | Participants with SAEs | 2 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 1000 mg/m^2Capecitabine | Participants with SAEs | 4 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 100 mg Dasatinib + 1000 mg/m^2Capecitabine | Participants with SAEs | 13 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 50 mg Dasatinib + 825 mg/m^2Capecitabine | Participants with Grade 3 - 4 SAEs | 2 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 825 mg/m^2Capecitabine | Participants with Grade 3 - 4 SAEs | 1 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 70 mg Dasatinib + 1000 mg/m^2Capecitabine | Participants with Grade 3 - 4 SAEs | 4 | participants | |
| Number of Participants With Deaths, Serious Adverse Events, Adverse Events, Adverse Events Leading to Discontinuation and Treatment-related Adverse Events - Safety Population | 100 mg Dasatinib + 1000 mg/m^2Capecitabine | Participants with Grade 3 - 4 SAEs | 11 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00452673/results